Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
29.96
-1.48 (-4.71%)
At close: Nov 20, 2026, 4:00 PM EST
30.20
+0.24 (0.80%)
After-hours: Nov 20, 2026, 5:33 PM EST
Viridian Therapeutics Revenue
Viridian Therapeutics had revenue of $25.75M in the quarter ending September 30, 2026, a decrease of -63.51%. This brings the company's total for the last twelve months to $26.31M, down -62.83% year-over-year. In the year 2025, Viridian Therapeutics had annual revenue of $70.85M with 23,359.93% growth. That makes Viridian Therapeutics the 32,218th largest company in the world by revenue and 4,221st in the United States.
Revenue (ttm)
$26.31M
Revenue Growth
-62.83%
P/S Ratio
129.32
Revenue / Employee
$104,401
Employees
252
Market Cap
3.40B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 70.85M | 70.55M | 23,359.93% |
| Dec 31, 2024 | 302.00K | -12.00K | -3.82% |
| Dec 31, 2023 | 314.00K | -1.46M | -82.28% |
| Dec 31, 2022 | 1.77M | -1.19M | -40.20% |
| Dec 31, 2021 | 2.96M | 1.91M | 182.19% |
| Dec 31, 2020 | 1.05M | -3.41M | -76.46% |
| Dec 31, 2019 | 4.46M | -3.93M | -46.80% |
| Dec 31, 2018 | 8.39M | 4.38M | 109.49% |
| Dec 31, 2017 | 4.00M | 526.00K | 15.13% |
| Dec 31, 2016 | 3.48M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.36B |
| Tarsus Pharmaceuticals | 682.20M |
| Arcutis Biotherapeutics | 508.68M |
| Iovance Biotherapeutics | 378.98M |
| AbCellera Biologics | 67.85M |
| Relay Therapeutics | 10.35M |
| Xenon Pharmaceuticals | 7.50M |
VRDN News
- 1 day ago - Viridian Therapeutics initiated with a Buy at BofA - TheFly
- 1 day ago - Viridian Therapeutics initiated with a Buy at BofA - TheFly
- 4 days ago - Viridian Therapeutics Transcript: Jefferies Global Healthcare Conference - Transcripts
- 10 days ago - Viridian Therapeutics price target raised to $39 from $34 at Wells Fargo - TheFly
- 11 days ago - Viridian Therapeutics Transcript: Study update - Transcripts
- 11 days ago - Viridian Therapeutics Press release: Study update - Filings
- 11 days ago - Viridian Therapeutics Slides: Study update - Filings
- 11 days ago - Viridian Therapeutics announces phase 1 results for VRDN-008 - TheFly